LGVN news

Latest 2 stories · newest Oct 26, 2026

LGVN

Longeveron announces key secondary endpoints met in ELPIS II trial

Longeveron's laromestrocel therapy met a secondary efficacy endpoint (MACE) in HLHS patients, triggering a meeting with the FDA despite missing the primary RVEF goal, representing a potential development breakthrough.

Regulatory Oct 26, 2026 sentiment +0.50 SEC filing ↗

LGVN

Laromestrocel fails primary endpoint in HLHS trial

The ELPIS II trial failed to meet its primary efficacy endpoint but showed improved transplant-free survival and fewer cardiovascular events. Longeveron will explore options to maximize shareholder value.

Guidance Sep 23, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same LGVN feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/LGVN/newsSTART FREE